[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-arterial-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-arterial-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,81,116,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100624292","shockfast-intravascular-lithotripsy-device-for-treatment-of-calcified-coronary-lesions-100624292",false,"NCT07407738","ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions","ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions, a Prospective, Randomised, International Trial: ShockFast IVL Trial","IVL","Inclusion Criteria:\n\n1. Patients aged ≥18 years undergoing PCI for stable or unstable angina or staged procedure after successful treatment of a myocardial infarction where heart enzymes are decreasing\n\n   Angiographic criteria:\n2. Native de novo coronary lesions\n3. Vessel diameter between 2.5mm - 4.0mm\n4. Lesion Length: ≤40mm\n5. Severe Calcification:\n\n   1. Calcification visible on the upper and the lower sides of the vessel wall in at least two angiographic projections that differ ≥ 60° from each other\n   2. Presence of severe calcified protruding noduli\n6. No flow disturbances at baseline (Thrombolysis in Myocardial Infarction \\[TIMI\\] 3 flow at baseline)\n7. Target lesion with diameter stenosis ≥70% by visual, or ≥50% with evidence of clinical ischemia\n\n   OCT Criteria:\n8. Total calcium arc \\> 180° or\n9. Presence of a protruding calcified noduli\n\nExclusion Criteria:\n\n1. Ejection fraction less than 25%\n2. Lesion located in Left Main (LM) coronary artery\n3. Calcifications located mostly \\> 0.5 mm from the vessel lumen.\n4. Severe renal Impairment; Serum Creatinine \\> 220 μmol or currently undergoing hemodialysis\n5. Severe lesion tortuosity where OCT is judged impossible to cross.\n6. Inability to tolerate dual antiplatelet therapy for 6 months or longer\n7. Inability to obtain inform consent or deemed poorly compliant by the investigator\n8. Presence of permanent pacemaker\n9. Angiographic evidence of thrombus in the target vessel\n10. Target lesion located at or involving within 5mm of the coronary ostium of the Left Anterior Descending artery (LAD), Left Circumflex artery (LCX)\n11. Target lesion is a chronic total occlusion (CTO)\n12. Presence of aneurysm within 10mm proximal or distal to the target lesion","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","Coronary artery disease is caused by narrowing of the artery lumen. Treatment with Percutaneous Coronary Intervention (PCI) may be needed. This is a minimally invasive procedure used to treat narrowed or blocked coronary arteries. Sometimes a stent is placed to keep the artery open. If the lesions in the coronary artery are calcified, this may cause difficulties for successful stent placement. The calcified plaques can be fractured via intravascular lithotripsy (IVL) with devices like ShockWave IVL and ShockFast IVL. The aim of this study is to compare the this relatively new ShockFast IVl with the more widely used ShockWave IVL.",[27,28],"Coronary Arterial Disease","Calcified Coronary Artery Disease",[30,31,32,15],"Shockwave Intravascular Lithotripsy","Shockfast Intravascular Lithotripsy","Coronary Calcified Lesion","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2026-02-16",{"date":41,"type":21},"2026-11-01",{"name":43,"class":44},"Shunmei Medical","INDUSTRY",11,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100641874","effect-of-dapagliflozin-on-right-ventricular-pulmonary-artery-coupling-after-off-pump-coronary-atery-bypass-grafting-100641874","NCT07601867","Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting","Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Artery Bypass Grafting: a Prospective Single-Center Study","DAPA-RV-CABG","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Elective isolated off-pump coronary artery bypass grafting (OPCAB)\n* Left ventricular ejection fraction (LVEF) \\\u003C 50% documented on pre-operative echocardiography\n* Written informed consent\n\nExclusion Criteria:\n\n* Concomitant valve surgery\n* Emergency or urgent CABG\n* Conversion to on-pump during surgery\n* Perioperative myocardial infarction (as defined by the Fourth Universal Definition of MI)\n* Cardiogenic shock\n* More than moderate valvular heart disease\n* Persistent atrial fibrillation or atrial flutter at the time of echocardiographic examination)\n* Previous CABG or any prior cardiac surgery\n* Severe chronic kidney disease (eGFR \\\u003C 25 mL\u002Fmin\u002F1.73 m²)\n* Contraindication to SGLT2 inhibitors\n* Inability to obtain adequate echocardiographic windows\n* Pregnancy or breastfeeding",{"count":55,"type":21},72,"OBSERVATIONAL","This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg\u002Fday on right ventricular-pulmonary artery coupling measured by the TAPSE\u002FPASP ratio in 72 patients with left ventricular ejection fraction \\\u003C50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE\u002FPASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).",[59,27],"Heart Failure",[61,62,63,64,65,66,67,68,69],"OPCAB","Right Ventricle","SGLT2 inhibitor","Dapagliflozin","TAPSE\u002FPASP","Pulmonary vascular resistance","KCCQ-23","CABG","RV-PA coupling","2026-06-15",{"date":72,"type":37},"2026-06-17",{"date":74,"type":21},"2026-07-01",{"date":76,"type":21},"2028-07-01",{"name":78,"class":79},"Pyatigorsk City Clinical Hospital Number 1","OTHER_GOV",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":80},"100622832","espb-vs-spsip-for-postoperative-analgesia-after-cabg-100622832","NCT07388745","ESPB vs SPSIP for Postoperative Analgesia After CABG","A Randomized Trial Comparing Erector Spinae Plane Block Versus Serratus Posterior Superior Intercostal Plane Block for Postoperative Analgesic Efficacy in Patients Undergoing Coronary Artery Bypass Graft Surgery","ESP-SPSIP-CABG","Inclusion Criteria:\n\n* Age 45-85 years\n* Scheduled for elective coronary artery bypass graft (CABG) surgery\n* American Society of Anesthesiologists (ASA) I-II-III\n* Patients who provide written informed consent and agree to participate in the study\n\nExclusion Criteria:\n\n* Emergency cases\n* ASA IV-V\n* Known allergy to local anesthetics\n* Coagulopathy (platelet count \\\u003C100,000\u002Fmm³, INR \\>1.5, aPTT \\>1.5× normal)\n* Infection at the block injection site\n* Pregnancy\n* Patients who do not provide written informed consent or decline to participate after being informed","45 Years","85 Years",{"count":92,"type":21},64,[24],"This prospective, randomized, active-controlled, double-blind, parallel-group study compares the postoperative analgesic efficacy and safety of ultrasound-guided bilateral Erector Spinae Plane Block (ESPB) versus bilateral Serratus Posterior Superior Intercostal Plane Block (SPSIPB) in adult patients (45-85 years, ASA I-III) undergoing elective coronary artery bypass graft surgery. The primary outcome is postoperative pain intensity assessed by Numeric Rating Scale (NRS) at 2, 4, 8, 16, 24, and 48 hours after surgery. Secondary outcomes include intraoperative fentanyl\u002Fremifentanil consumption, postoperative morphine consumption, patient-controlled analgesia (PCA) demand\u002Fdelivery parameters (if PCA is used), need for rescue analgesics, extubation and mobilization times, peak inspiratory flow measured by incentive spirometry at predefined time points, ICU and hospital length of stay, recovery quality (QoR-15 at 0, 24, and 48 hours), mortality, and block-related adverse events.",[27,96,97],"Coronary Artery Bypass Grafting (CABG) Surgery","Postoperative Pain Management",[99,100,101,102,103,104,105],"Coronary Artery Bypass Grafting","Erector Spinae Plane Block","Serratus Posterior Superior Intercostal Plane Block","Regional Anesthesia","Ultrasound-Guided Nerve Block","Postoperative Pain","Numeric Rating Scale","2026-05-10",{"date":108,"type":37},"2026-05-13",{"date":110,"type":37},"2026-03-01",{"date":112,"type":21},"2026-08-31",{"name":114,"class":115},"Kutahya Health Sciences University","OTHER",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":56,"phases":4,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":80},"100615534","optical-coherence-tomography-prognostic-value-and-artificial-intelligence-100615534","NCT07293858","Optical Coherence Tomography: Prognostic Value and Artificial Intelligence","ORANGE","Inclusion Criteria:\n\n* All consecutive patients undergoing intracoronary OCT imaging at the Radboud University Medical Center, and any additional centers that may join the study in the future.\n* OCT performed at the discretion of the treating physician, according to contemporary clinical guidelines.\n* Written informed consent obtained after the procedure.\n\nExclusion Criteria:\n\n* Patients who decline or are unable to provide informed consent. (Only patients who provide consent can be included.\n* Patients for whom follow-up or data collection is not feasible (e.g., no valid contact details).",{"count":124,"type":21},1000,"10 Years","This study aims to evaluate the prognostic value of optical coherence tomography (OCT) imaging of the coronary arteries. OCT provides high-resolution images of the vessel wall and stented segments during routine cardiac catheterization. All patients who undergo OCT as part of their clinical care are invited to participate in this prospective registry.\n\nThe study will examine whether specific OCT-derived characteristics-such as plaque morphology, vulnerable features, or indicators of stent optimization-are associated with long-term clinical outcomes. Follow-up information on symptoms, medication use, hospitalizations, cardiac procedures, and major cardiac events will be collected through medical records, questionnaires, and national registry data over a period of up to 10 years.\n\nIn addition, pseudonymized OCT pullbacks will be used to support the development of an artificial intelligence (AI) algorithm for automated annotation of OCT images. This algorithm may help improve the clinical interpretation of OCT by identifying relevant imaging features in a consistent and efficient manner.\n\nParticipation is voluntary and includes permission to use clinical data, OCT images, and follow-up information for research purposes. Data are coded to protect participant privacy and stored securely according to applicable regulations. The results of this study may contribute to better understanding of coronary plaque characteristics and may support improved decision-making in interventional cardiology.",[27],[129,130],"Optical Coherence Tomography","Artificial Intelligence","2025-12-08",{"date":133,"type":37},"2025-12-19",{"date":135,"type":37},"2021-11-26",{"date":137,"type":21},"2028-12-31",{"name":139,"class":115},"Radboud University Medical Center",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":80},"100601360","safety-and-effectiveness-of-the-single-use-coronary-forward-intravascular-lithotripsy-catheter-combined-with-the-intravascular-lithotripsy-therapy-device-100601360","NCT07109479","Safety and Effectiveness of the Single-Use Coronary Forward Intravascular Lithotripsy Catheter Combined With the Intravascular Lithotripsy Therapy Device","A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the Single-Use Coronary Forward Intravascular Lithotripsy Catheter Combined With the Intravascular Lithotripsy Therapy Device for Pre-treatment of De Novo Calcified Stenotic Coronary Lesion","FORWARD IVL","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n* 1\\) Age ≥18 years, male or female.\n\n  2)Primary coronary artery disease (with evidence of asymptomatic myocardial ischemia, stable\u002Funstable angina, or old MI) scheduled for non-emergent PCI.\n\n  3)Pre-procedure Left Ventricular Ejection Fraction (LVEF) ≥30%.\n\n  4)Voluntarily participate in this study and sign Informed Consent Form (ICF), willing to comply with study procedures and follow-up.\n\nAngiographic Inclusion Criteria:\n\n1. Target lesion is de novo calcified stenotic coronary lesion with no prior intervention.\n2. Target lesion reference vessel diameter is 2.5-4.0 mm.\n3. Target lesion meets ONE of the following:\n\n   RCT part: Moderate-to-severe calcification AND stenosis ≥90% and \\\u003C100% (length ≤60 mm). (Moderate Calcification: Clearly visible high-density shadows during cardiac motion; Severe Calcification: Clearly visible high-density shadows visible without cardiac motion).\n\n   Single-arm part: Calcified lesion AND Chronic Total Occlusion (CTO) (length ≤20 mm).\n4. Guidewire positioned in the true lumen distal to the target lesion and not in the subintimal space prior to device use.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria\n\n* 1\\) Planning use of scoring\u002Fcutting balloons, Excimer Laser Coronary Atherectomy (ELCA), or Coronary Intravascular Lithotripsy balloons for calcified lesion modification prior to study device use.\n\n  2\\) NYHA Class III or IV.\n\n  3\\) Currently on dialysis or serum creatinine level \\>2.5 mg\u002FdL (or 221 µmol\u002FL).\n\n  4\\) Severe coagulation disorder (platelet count \\\u003C100×10⁹\u002FL).\n\n  5\\) Hyperviscosity diseases (e.g., polycythemia vera, platelet count \\>750×10⁹\u002FL).\n\n  6\\) Cardiac shock with clinical signs or symptoms.\n\n  7\\) Active systemic infection.\n\n  8\\) Moderate-to-severe anemia (hemoglobin \\\u003C90 g\u002FL).\n\n  9\\) Acute Myocardial Infarction within 1 month prior to procedure.\n\n  10\\) Stroke or Transient Ischemic Attack (TIA) within 3 months prior to procedure.\n\n  11\\) Active gastrointestinal ulcer or bleeding within 3 months prior to procedure.\n\n  12\\) Expected life expectancy \\\u003C12 months as assessed by the investigator.\n\n  13\\) Known intolerance to antiplatelet or anticoagulant therapy.\n\n  14\\) Known allergy to study device components or contrast media.\n\n  15\\) Known pregnancy or lactation (female subjects).\n\n  16\\) Participating or planning to participate in another drug or device clinical trial.\n\n  17\\) Other conditions deemed unsuitable for participation by the investigator\n\nAngiographic Exclusion Criteria:\n\n1. Unprotected left main coronary artery disease (stenosis \\>50%).\n2. Serious angiographic complication in the target vessel prior to study device use.\n3. Presence of thrombus or suspected thrombus in the target vessel.\n4. Aneurysm within 10 mm of the target lesion in the target vessel.\n5. Presence of other lesions with stenosis \\>50% within the target vessel.\n6. CTO lesion with excessive tortuosity (\\>45°) or length \\>20 mm.\n7. Stent implanted within 5 mm proximal or distal to the target lesion.\n8. Target lesion accessible only via saphenous vein graft (SVG) or arterial graft.\n9. Failure of guidewire to successfully cross the target lesion.\n10. Planned use of Antegrade Dissection Re-entry (ADR), Retrograde Wiring (RW), or Retrograde Dissection Re-entry (RDR) techniques",{"count":149,"type":21},180,[24],"The FORWARD IVL trial is a Prospective, Multicenter Study conducted to assess the safety and effectiveness of the Single-Use Coronary Forward Intravascular Lithotripsy Catheter combined with the Intravascular Lithotripsy Therapy Device for the pre-treatment of calcified, stenotic de novo coronary artery lesions .",[27],"NOT_YET_RECRUITING","2025-07-30",{"date":156,"type":37},"2025-08-07",{"date":158,"type":21},"2025-10-01",{"date":160,"type":21},"2027-12-31",{"name":162,"class":44},"Spectrumedics Medical Technology(Shanghai)Co.,Ltd"]